HRT extended use not cardioprotective
Executive Summary
Continued use of hormone replacement therapy by postmenopausal women with coronary heart disease does not offer cardioprotective benefit, Wyeth-sponsored Heart and Estrogen/Progestin Replacement Study II data published in June 3 Journal of the American Medical Association show. HERS II found no reduced risk of CHD events for 1,380 women taking .625 mg of conjugated estrogens/2.5 mg of medroxyprogesterone daily during 2.7-year open-label study. HERS II is a follow-up to the 4.1 year HERS trial, which suggested a decreased risk for the third through fifth years of hormone therapy (1"The Pink Sheet" Aug. 24, 1998, p. 11)...